Week In Review: Big Deals Headline This Week's Life Science News

Shanghai Fosun Pharma offered as much as $1.5 billion to acquire India's Gland Pharma, an injectible drug maker; Ping An Haoyisheng (Ping An My Doctor), a mobile health app, raised $500 million in a Series A round at a $3 billion valuation; WI Harper Group closed its eighth fund at $175 million for US-China high-tech investments including life science; Eu Yan Sang International, a Singapore TCM company, received a $196 million privatization offer; BGI of Shenzhen will distribute Singapore's Clearbridge BioMedics liquid biopsy in China through its clinical diagnostics division; HemaCare, a Los Angeles provider of cell and tissue collection products, partnered its China distribution with Shanghai's MT-Biological Science and Technology; Korea's ViroMed was granted US Fast Track designation for a novel clinical-stage gene therapy; Solasia Pharma, a Japanese in-licensing company, filed for approval of an oral mucositis treatment in China and Japan; and China's regulators mandated price cuts ranging from half to two-thirds on three expensive drugs, two imported and one domestic.